Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin.
We previously showed that the risk of major hemorrhage in patients with venous thromboembolism treated with warfarin was strongly related to duration of anticoagulant therapy. We here report the results of a more detailed analysis of factors other than duration of warfarin therapy associated with the risk of hemorrhage in these patients. Almost 7% of patients had a major hemorrhage on warfarin and an additional 23.7% had at least one minor bleeding episode. Age, female sex, and congestive heart failure were associated with small increases in the risk of major hemorrhage but not with the risk of minor bleeding. A prothrombin time ratio greater than 2.5 was associated with a fourteen-fold increase in the risk of a major hemorrhage (95% CI 5.1, 42.7), but major hemorrhages occurred in patients on warfarin at all measured values of the prothrombin time ratio. Taken together with the findings from our previous analysis, the study suggests that prevention of bleeding in patients on warfarin would best be accomplished by minimizing the duration of warfarin therapy, by scrupulous monitoring of the prothrombin time ratio, and by considering the "therapeutic range" for the prothrombin time ratio to be somewhat less than 2.0-2.5.
Division of Research, Kaiser Permanente Medical Care Program, Oakland, California.
D B
DB
Petitti
B L
BL
Strom
K L
KL
Melmon
D000328:Adult; D000368:Aged; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011517:Prothrombin Time; D011655:Pulmonary Embolism / Q000188:drug therapy; D012307:Risk Factors; D013924:Thrombophlebitis / Q000188:drug therapy; D013997:Time Factors; D014859:Warfarin / Q000009:adverse effects*
D014859:Warfarin